CHRM3-AS2

Across TCGA pan-cancer cohorts, CHRM3-AS2 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of CHRM3-AS2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CHRM3-AS2 RNA is repressed in tumor relative to normal tissue. In most cancer types CHRM3-AS2 is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, KIRP, and KICH are the cancer types where CHRM3-AS2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CHRM3-AS2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	−0.449	<.001	11	view →
KIRP	Male	II,III,IV	−0.574	<.001	9	view →
KICH	All	All	−0.355	<.001	6	view →
COAD	Female	All	−0.296	<.001	6	view →
THCA	All	All	−0.324	.013	2	view →
BRCA	All	III,IV	−0.111	.002	2	view →
CHOL	All	II,III,IV	+0.024	.037	2	view →
LUSC	Male	II,III,IV	−0.193	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

CHRM3-AS2–KIRC

Open the KIRC breakdown →